Two-year outcomes of "treat and extend" intravitreal therapy for neovascular age-related macular degeneration.
暂无分享,去创建一个
R. Guymer | J. Simpson | M. Gillies | I. McAllister | N. Morlet | A. Hunyor | A. Campain | D. Barthelmes | J. Arnold | R. Essex
[1] R. Avery. Re: Berg et al.: Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol (Ophthalmology 2015;122:146-52). , 2016, Ophthalmology.
[2] R. Guymer,et al. Time to initial clinician-reported inactivation of neovascular age-related macular degeneration treated primarily with ranibizumab. , 2015, Ophthalmology.
[3] M. Gillies,et al. REASONS FOR DISCONTINUATION OF INTRAVITREAL VASCULAR ENDOTHELIAL GROWTH FACTOR INHIBITORS IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2014, Retina.
[4] R. Guymer,et al. ANTI-VEGF TREATMENT IN NEOVASCULAR AGE–RELATED MACULAR DEGENERATION: A Treat-and-Extend Protocol Over 2 Years , 2014, Retina.
[5] U Chakravarthy,et al. The neovascular age-related macular degeneration database: multicenter study of 92 976 ranibizumab injections: report 1: visual acuity. , 2014, Ophthalmology.
[6] J. Keeffe,et al. EFFICIENT CAPTURE OF HIGH-QUALITY DATA ON OUTCOMES OF TREATMENT FOR MACULAR DISEASES: The Fight Retinal Blindness! Project , 2014, Retina.
[7] B. Kirchhof,et al. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration. , 2013, American journal of ophthalmology.
[8] R. Guymer,et al. Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naive eyes. , 2013, Investigative ophthalmology & visual science.
[9] P. Ng,et al. A 12-MONTH PROSPECTIVE TRIAL OF INJECT AND EXTEND REGIMEN FOR RANIBIZUMAB TREATMENT OF AGE-RELATED MACULAR DEGENERATION , 2013, Retina.
[10] Allen C Ho,et al. Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. , 2013, Ophthalmology.
[11] A. Ho,et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. , 2012, Ophthalmology.
[12] G. Ying,et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. , 2012, Ophthalmology.
[13] C. Regillo,et al. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact. , 2012, American journal of ophthalmology.
[14] Glenn J Jaffe,et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. , 2011, The New England journal of medicine.
[15] R. Tadayoni,et al. INJECT AND EXTEND DOSING VERSUS DOSING AS NEEDED: A Comparative Retrospective Study of Ranibizumab in Exudative Age-Related Macular Degeneration , 2011, Retina.
[16] C. Regillo,et al. A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact. , 2010, Ophthalmology.
[17] R. Spaide. Ranibizumab according to need: a treatment for age-related macular degeneration. , 2007, American journal of ophthalmology.
[18] K. Eng,et al. Ranibizumab in neovascular age-related macular degeneration , 2006, Clinical interventions in aging.
[19] Susan Schneider,et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. , 2006, The New England journal of medicine.
[20] Terje R Pedersen,et al. Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. , 2015, Ophthalmology.
[21] R Core Team,et al. R: A language and environment for statistical computing. , 2014 .
[22] Allen C Ho,et al. Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. , 2014, Ophthalmology.
[23] Philip J Rosenfeld,et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. , 2009, American journal of ophthalmology.
[24] Peter K. Kaiser,et al. ANCHOR STUDY GROUP. RANIBIZUMAB VERSUS VERTEPORFIN FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION , 2006 .
[25] T. Hastie,et al. Statistical Models in S , 1991 .